It has been described that the innate immune response has a role in AD, and stimulation of the innate immune system via Toll-like receptor 9 (TLR9) agonists, such as type B CpG oligodeoxynucleotides (ODNs) is an effective and safe method to reduce tau-related pathology in AD mouse model [56,57]. This evidence concerns the gene MAPT and Alzheimer disease.